Inosine Ameliorates the Injurious Microenvironment for Oligodendrocyte Precursor Cells by Suppressing Microglial Activation and Neuroinflammation In Vitro
Neurochemical Research · 2026-06 · 51 (3)
DOI: 10.1007/s11064-026-04771-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, online erschienen am 20.05.2026. Verfasst von Yong Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy and Histoembryology, Basic Medical College of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China. Hauptthemen laut MEDLINE: Microglia, Oligodendrocyte Precursor Cells, Inosine, Neuroinflammatory Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Ningxia.
Abstract (Originalsprache)
Neonatal white matter injury (WMI), a leading cause of cerebral palsy, results from microglial-driven neuroinflammation that affects oligodendrocyte precursor cell (OPC) survival and differentiation. Our prior in vivo research indicated that inosine may protect against maternal inflammation-induced WMI by modulating microglial polarization and inhibiting TLR4/MyD88/NF-κB signaling, but its direct effects on microglia are unknown. This in vitro study used a microglia-conditioned medium (MCM)-OPC approach to explore this question. Primary microglia were stimulated with lipopolysaccharide (LPS) and treated with inosine, followed by the measurement of inflammatory cytokines (TNF-α, IL-1β, IL-6) and TLR4 pathway proteins via ELISA and Western blot. MCM derived from differentially treated microglia was then applied to OPC cultures, where OPC viability, death, proliferation, and differentiation were assessed using CCK-8 assay, propidium iodide (PI) staining, immunofluorescence, and Western blot. Inosine co-treatment significantly decreased LPS-induced secretion of TNF-α, IL-1β, and IL-6 from microglia (P < 0.05) and downregulated TLR4, MyD88, and p-NF-κB p65 expression (P < 0.001, P < 0.01). MCM from inosine-treated microglia mitigated OPC damage caused by activated microglia, as demonstrated by enhanced OPC viability (P < 0.01), reduced apoptosis (evidenced by decreased PI positivity and Cleaved Caspase-3 expression, P < 0.01, P < 0.05), increased proliferation (indicated by elevated Ki67 positivity and NG2 expression, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Anatomy and Histoembryology, Basic Medical College of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China.
- Department of Pathology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China. sunjp79@163.com.
- Department of Human Anatomy and Histoembryology, Basic Medical College of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China. niujg@nxmu.edu.cn.
- Department of Human Anatomy and Histoembryology, Basic Medical College of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China. 20030005@nxmu.edu.cn.
Förderung
- Natural Science Foundation of Ningxia
Zitieren
APA
Han, Y., Chen, J., Wang, P., Sun, J., Niu, J., & Ma, Q. (2026). Inosine Ameliorates the Injurious Microenvironment for Oligodendrocyte Precursor Cells by Suppressing Microglial Activation and Neuroinflammation In Vitro. Neurochemical Research, 51(3). https://doi.org/10.1007/s11064-026-04771-1
Vancouver
Han Y, Chen J, Wang P, Sun J, Niu J, Ma Q. Inosine Ameliorates the Injurious Microenvironment for Oligodendrocyte Precursor Cells by Suppressing Microglial Activation and Neuroinflammation In Vitro. Neurochemical Research. 2026;51(3). doi:10.1007/s11064-026-04771-1
BibTeX
@article{Han2026,
author = {Han, Yong and Chen, Jin and Wang, Peilian and Sun, Jinping and Niu, Jianguo and Ma, Quanrui},
title = {Inosine Ameliorates the Injurious Microenvironment for Oligodendrocyte Precursor Cells by Suppressing Microglial Activation and Neuroinflammation In Vitro},
journal = {Neurochemical Research},
year = {2026},
volume = {51},
number = {3},
doi = {10.1007/s11064-026-04771-1}
}
EUVIMED